Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 67, Issue 3, Pages 253-260
Publisher
Springer Nature
Online
2010-11-03
DOI
10.1007/s00228-010-0914-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and Effectiveness
- (2009) J. Cadena et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Voriconazole Pharmacokinetics in Liver Transplant Recipients
- (2009) H. J. Johnson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
- (2009) Ina Scholz et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
- (2009) Kazuaki Matsumoto et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations
- (2009) Jeannina Smith et al. THERAPEUTIC DRUG MONITORING
- Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients
- (2009) M. Berge et al. Transplant Infectious Disease
- Inhibition of Voriconazole Metabolism by Chloramphenicol in an Adolescent with Central Nervous System Aspergillosis
- (2008) V. Hafner et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
- (2008) M. O. Karlsson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
- (2008) Thomas J. Walsh et al. CLINICAL INFECTIOUS DISEASES
- The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
- (2008) Guo Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
- (2008) Johanna Weiss et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Neuromuscular Painful Disorders: a Rare Side Effect of Voriconazole in Lung Transplant Patients Under Tacrolimus
- (2008) V. Boussaud et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes
- (2007) A. Pascual et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetic Interaction Between Voriconazole and Efavirenz at Steady State in Healthy Male Subjects
- (2007) Ping Liu et al. JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started